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A 60-year-old nulligravida woman of British descent presented for
evaluation of an incidental ﬁnding of aortocaval lymphadenopathy.
The patient has a history of estrogen receptor positive, poorly differen-
tiated, invasive ductal carcinomadiagnosed at age 51. Her family history
is remarkable, ovarian cancer in her mother at age 52, breast cancer at
age 80 in a maternal aunt, pancreatic cancer in a maternal cousin at
age 60, and a paternal auntwith breast cancer at age 50 (Fig. 1). The pa-
tient had previously tested negative formutations in BRCA1/2. However,
due to her family history she underwent a total abdominal hysterecto-
my with BSO for risk reduction at age 41. The pathology was benign.tially for renal stone evaluation, demonstrated a 2.9 × 2.6 × 1.5 cm lob-1. Introduction
Primary Peritoneal Carcinoma (PPC) is a cancer of the abdominal
peritoneal lining without involvement of the ovaries or identiﬁable pri-
mary tumor. Its estimated annual incidence in the United States is 0.46
per 100,000 women(Goodman et al., 2009). The actual incidence of
low-grade serous PPC is much lower (b1/150,000) (Rothacker et al.,
1995). Most cases are serous subtype with cellular origin identical to
that of epithelial ovarian carcinoma. PPC often mimics ovarian and
fallopian tube cancers. It accounts for roughly 10%of ovarian carcinomas
that have been presumably misdiagnosed (Rothacker et al., 1995).
Women undergoing prophylactic bilateral salpingo-oophorectomy
(BSO) can still develop PPC years later, suggesting that certain epithelial
peritoneal cancers do not originate from the ovarian surface. Instead,
ovarian epithelial tumors and PPC are hypothesized to share a common
embryologic originwith similar germline and somaticmutations. In cur-
rent literature, nearly all PPC cases have been reported inwomenwith a
known BRCA1/2 germlinemutation. However, there have beenminimal
studies on genetic testing outside of BRCA1/2mutations in patients with
PPC. Here, we report a case of a BRCA1/2-negative patient who had un-
dergone prophylactic BSO and presented years later with PPC and was
subsequently found to carry a mutation in PALB2.chool of Medicine, United States.
. George).
. This is an open access article underAn abdominal computed tomography CTwithout contrast, done ini-
ulated right retroperitoneal mass anterior to the inferior vena cava at
the level of L3–L4 with both hypo-enhancing and cystic components
(Fig. 2A). Subsequent positron emission tomography (PET) scan
showed a partially calciﬁed 2.3 × 1.3 cm hypermetabolic distal
aortocaval lymph node, standard uptake value 6.5 (Fig. 2B). CT
guided biopsy showed papillary adenocarcinoma with psammoma
bodies. The tumor was positive for CA-125, PAX8, and ER. This
immunophenotype and histomorphologywere consistentwith a serous
carcinoma rather than a breast primary.
The patient underwent a robotic lysis of adhesions, right periaortic
lymph node dissection, and omentectomy for suspected PPC. Intraoper-
ative ﬁndings included a 4 cm right periaortic lymph node and omental
adhesions to the upper abdomen. No gross residual disease nor evi-
dence of carcinomatosis were noted. Pelvic washing and omentum pa-
thology were negative for malignancy. The right periaortic lymph node
was positive for metastatic papillary carcinoma in a background with
numerous psammoma bodies (Fig. 3A, B). Immunohistochemistry
demonstrated that the tumor cells were positive for p53 (heteroge-
neous, “wild-type” pattern), WT1, ER (diffuse, strong pattern) and
PAX8 (Fig. 3C, D). The tumor cells showed a low mitotic index and
relatively uniform cytomorphology, with b3 times variation in size.
Based on the morphologic and immunohistochemical ﬁndings, the
diagnosis of a low-grade serous carcinoma, of likely peritoneal ori-
gin, was established.
Given the patient's strong personal and family history of cancer, she
underwent genetic counseling and further genetic testing for a multi-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Pedigree of family with PALB2mutation and BRIP1 VUS. Circles = females; squares = males; ﬁlled symbols = affected with cancer; slashed symbols = deceased; +=mutation
carrier; d. = death, number denotes age, arrow denotes proband.
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following genes: ATM, BARD1, BRIP1, CDH1, CHEK2, EPCAM, FANCC,
MLH1, MSH2,MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11,
TP53, and XRCC2. A pathogenic variant was identiﬁed in PALB2, denoted
c.3113G N A, and a variant of uncertain signiﬁcance (VUS)was identiﬁed
in BRIP1, denoted c.2220G N T.3. Discussion
Themutation in PALB2 is denoted c.3113G N A (W1038X) and results
in a change from tryptophan to a premature stop codon. This mutation
has beenwidely reported in literature and is considered to be a founder
mutation originating in the United Kingdom (Southey et al., 2010;
Casadei, 2011; Slater et al., 2010). It is shown to produce three different
transcripts, all ofwhich are damaging to the protein, either through pro-
tein truncation or nonsense-mediated mRNA decay (Casadei, 2011).
The increased risk of breast cancer conferred by truncating muta-
tions in PALB2 has been demonstrated in population-based studies of
women with breast cancer (Southey et al., 2010), as well as in family
studies (Antoniou et al., 2014).Womenwith a PALB2mutation are esti-
mated to have a 2 to 4-fold increased breast cancer risk, with the level of
risk dependent on the strength of the family history (Antoniou et al.,
2014). Interestingly, the c.3113G N A PALB2 founder mutation is esti-
mated throughmodiﬁed segregation analysis to have a 91% cumulative
risk of breast cancer to age 703.
Although an increased risk of pancreatic cancer has been associated
with PALB2mutations, the exact risk has not yet been well establishedFig. 2. (A) Abdominal CT without contrast showing a 2.9 × 2.6 × 1.5 cm lobulated right retro
enhancing and cystic components. (B) PET scan partially calciﬁed 2.3 × 1.3 cm hypermetabolic(Slater et al., 2010), an increased risk for ovarian cancer in PALB2muta-
tion carriers has been proposed as well (Walsh et al., 2011).
It is estimated that one in ﬁve ovarian carcinomas are associated
with loss-of-function mutations in a tumor suppressor gene (Kanchi et
al., 2014). In a study of 360 unselected primary ovarian, peritoneal,
and fallopian tube cancer genes, BRCA1 and BRCA2 mutations were de-
tected in 18% of patients and 6% had germlinemutations in 10 addition-
al tumor suppressor or DNAmismatch repair genes(Walsh et al., 2011).
Among these included PALB2, which co-localizes with BRCA2 in the nu-
cleus, promotes its stability, and facilitates its repair functions (Xia et al.,
2006). Thus,mutations in PALB2 disrupt BRCA2 tumor suppression func-
tion and predispose carriers to similar cancers.
PPC is a relatively rare classiﬁcation of serous cancers. A large pro-
spective study of female BRCA1/2-mutation carriers estimated that the
risk of PPC in 20 years following prophylactic BSO is 3.9% for BRCA1mu-
tation carriers and 1.9% for BRCA2mutation carriers. On average, PPC is
diagnosed 6.1 years after surgery and the 5-year survival rate is 38.4%
(Finch et al., 2014). The risk of PPC was higher among women who
underwent BSO between the ages of 40 and 50 compared to women
who underwent BSO before the age of 40. PPC after BSO has also been
reported in patients with Lynch syndrome (Schmeler et al., 2010). Of
48 patients with PPC reported in Walsh et al. (Walsh et al., 2011), 13
(27%) carried germline mutations in one of the 12 genes studied. One
patient was reported to carry a mutation in PALB2, further implicating
PALB2 as an ovarian cancer predisposition gene.
To our knowledge, this is the ﬁrst report of PPC diagnosed in a
woman 19 years post TAH-BSO in a BRCA1/2 negative, PALB2-mutation
carrier. Given the rarity of PALB2mutations and since prophylactic BSOperitoneal mass anterior to the inferior vena cava at the level of L3-L4 with both hypo-
distal aortocaval lymph node, SUV 6.5.
Fig. 3. (A), (B) Biopsy of right periaortic lymph node showing metastatic papillary carcinoma, with scattered psammoma bodies in the background of numerous psammoma bodies
(corresponding to hematoxylin and eosin [H&E] stained slides at 200× and 400× power). (C) Immunostain of right periaortic lymph node with PAX8 positive status. The tumor cells
stained positive for PAX8 and (D) ER, in a strong and diffuse pattern Immunostain of right periaortic lymph node with diffuse, strong ER positive status.
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more information to the mounting data that PALB2may be a signiﬁcant
risk gene in ovarian cancer predisposition(Daly et al., 2016).
Deleterious germlinemutations in BRIP1 are associated with a mod-
erate increase in ovarian cancer risk of 5.8%13. The BRIP1 variant of un-
certain signiﬁcance (VUS) identiﬁed in our patient is c.2220G N T,
leading to a substitution of glutamine with histidine at codon 740 of
the BRIP1 protein (Q740H). This variant was found to bemore common
in patients with ovarian cancer compared to controls (Ramus et al.,
2015). However, the variant that occurs is observedwith allele frequen-
cies of 0.1% in the NHLBI Exome Sequencing Project. Therefore, when
VUS are identiﬁed, patient recommendations should be based on that
individual's personal and family history, not the VUS14.
This patient's presentation of PPC 19 years after prophylactic BSO
and BRCA1/2-negative testing raises awareness for the importance of
further genetic characterization. As sequencing technologies and medi-
cal guidelines continue to advance, testing for a wider array of germline
mutations can be critical in today's clinical practice. With increased
availability and rapidly decreasing costs, there are clear advantages to
simultaneous multi-gene testing in ovarian cancer patients (Norquist
et al., 2016).Multi-gene testingwill have an important role in advancing
screening strategies to evaluate for carcinoma predisposition (Kanchi et
al., 2014). It will improve risk assessment and advance targeted therapy
while minimizing unnecessary treatments. Currently, there is minimalliterature regarding the association of PALB2 and additional cancer
risks such as ovarian, fallopian tube and PPC. More studies are needed
to further evaluate the cancer risk spectrum associated with this and
other tumor suppressor genes.
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